Document Detail


An update on the controversies of tocolytic therapy for the prevention of preterm birth.
MedLine Citation:
PMID:  12580832     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Preterm birth is the major cause of perinatal mortality and morbidity in the developed world. Where there are no contraindications to their use, tocolytics can improve neonatal survival rates by approximately 3% per day between 23 and 27 weeks gestation with a concomitant reduction in morbidity. The ultimate aim of tocolytic therapy is to prolong pregnancy until growth and maturation is complete, but even short-term delay may enable the administration of antepartum glucocorticoids to reduce hyaline membrane disease or to arrange transfer to a center with neonatal intensive care facilities. Both of these have been shown to reduce neonatal mortality and morbidity. Until recently, none of the currently used tocolytics, whether licensed or unlicensed, were developed specifically for the inhibition of preterm labor and consequently, they exhibit various potentially serious side-effects. As a result of the recent licensing of the oxytocin antagonist, atosiban, developed for the treatment of preterm labor and due to its high utero-specificity, obstetricians have experienced an advance in their options for the management of spontaneous preterm labor.
Authors:
Ingemar Ingemarsson; Ronald F Lamont
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Acta obstetricia et gynecologica Scandinavica     Volume:  82     ISSN:  0001-6349     ISO Abbreviation:  Acta Obstet Gynecol Scand     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-02-12     Completed Date:  2003-03-21     Revised Date:  2008-09-03    
Medline Journal Info:
Nlm Unique ID:  0370343     Medline TA:  Acta Obstet Gynecol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  1-9     Citation Subset:  IM    
Affiliation:
Departments Obstetrics and Gynecology, University Hospital, Lund, Sweden. ingemar.ingemarsson@gyn.lu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Agonists / therapeutic use
Calcium Channel Blockers / therapeutic use
Cyclooxygenase Inhibitors / therapeutic use
Female
Humans
Magnesium Sulfate / therapeutic use
Nitric Oxide Donors / therapeutic use
Obstetric Labor, Premature / prevention & control*
Pregnancy
Pregnancy Outcome
Prostaglandin-Endoperoxide Synthases / drug effects
Tocolytic Agents / therapeutic use*
Vasotocin / analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Calcium Channel Blockers; 0/Cyclooxygenase Inhibitors; 0/Nitric Oxide Donors; 0/Tocolytic Agents; 7487-88-9/Magnesium Sulfate; 9034-50-8/Vasotocin; 90779-69-4/atosiban; EC 1.14.99.1/Prostaglandin-Endoperoxide Synthases
Comments/Corrections
Comment In:
Acta Obstet Gynecol Scand. 2004 Apr;83(4):414   [PMID:  15005795 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alterations of rCBF and mitochondrial dysfunction in major depressive disorder: a case report.
Next Document:  An evaluation of midwives' counseling of pregnant women in fear of childbirth.